MP70-20 OUTCOMES OF SALVAGE CRYOABLATION FOR LOCALIZED RADIO-RECURRENT PROSTATE CANCER: A SINGLE SURGEON EXPERIENCE

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy II (MP70)1 Apr 2020MP70-20 OUTCOMES OF SALVAGE CRYOABLATION FOR LOCALIZED RADIO-RECURRENT PROSTATE CANCER: A SINGLE SURGEON EXPERIENCE Achankeng Afiadata*, Paul Prillaman, and Robert Given Achankeng Afiadata*Achankeng Afiadata* More articles by this author , Paul PrillamanPaul Prillaman More articles by this author , and Robert GivenRobert Given More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000950.020AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cryoablation is a well-known versatile treatment modality for localized prostate cancer with reasonable functional outcomes. It is readily used in the setting of radio-recurrent, localized disease as opposed to salvage prostatectomy owing to less associated morbidity. Literature on long-term outcomes of salvage cryoablation is sparse. We investigated the oncologic outcomes and complications of salvage cryoablation for localized, radio-recurrent prostate cancer. METHODS: Retrospective review of patients who underwent salvage cryoablation for radio-recurrent prostate cancer at our institution from 2003 to 2019. Included patients had biopsy-proven local recurrence, and negative metastatic workup. Preoperative data, follow-up, oncologic outcomes, and associated morbidity were obtained. RESULTS: Eighty-six patients had salvage cryoablation for localized, radio-recurrent prostate cancer at our institution during the 16-year period. Mean age (SD) of patients was 71 (8), with Caucasian males making up 59% of the population. Majority of patients had prior external beam radiotherapy (EBRT), 82.6%, with a mean pre-cryoablation PSA (SD) of 2.5 (0.9) ng/mL. Median (IQR) follow up was 55.2 (21-94.8) months. Forty-two patients had no evidence of disease (NED), 52% of patients with pre-PSA of <4 had NED compared to 44.4% for pre-PSA ≥4. Median (IQR) biochemical free survival was 64 (30-140) months; 75 (36-140) months for pre-PSA <4, and 48 (24-84) months for pre-PSA ≥4 (P=0.0735). Long-term associated morbidities included: incontinence (26.7%), urethral stricture/stenosis (24.7%), and fistula (3.5%). CONCLUSIONS: Earlier (PSA <4 ng/mL) salvage cryoablation for localized radio-recurrent prostate cancer portends better oncological outcomes. Counsel patients on high rate of long-term incontinence and urethral stricture/stenosis associated with treatment. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1063-e1063 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Achankeng Afiadata* More articles by this author Paul Prillaman More articles by this author Robert Given More articles by this author Expand All Advertisement PDF downloadLoading ...